Fujairah Mountain Shooting Championship Returns for a New Edition in February 2025
9.9.2024 17:44:00 CEST | Business Wire | Press release
The Fujairah Shooting Club announces the important dates, side events, ambassadors and launch of the website of the second edition of Fujairah Mountain Shooting Championship
Following the resounding success of its inaugural edition in 2023, Fujairah Shooting Club has announced the return of the Fujairah Mountain Shooting Championship (FMSC) and the launch of the championship's official website for its second edition. The unparalleled and challenging sporting event will return in February 2025 and will be held under the patronage of His Highness Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah.
The championship, which will run from February 1 to 8, 2025, in Dibba, Fujairah, UAE, will feature challenging layouts, exhilarating side events, and the chance to experience the natural beauty of the Emirate. The main championship, which will be held from February 5 to 8, will feature Super Sporting with 240 clays, a total prize of USD 300,000, and USD 50,000 for 100 flash clays.
The preliminary competitions of FMSC 2025 will be held from February 1 to 4 and will feature 50 clays of English Sporting with a total prize pool of USD 40,000 across four categories. The opening ceremony will be held on February 4, and the awards ceremony is scheduled for February 8, 2025.
The main championship will feature 24 stands, each equipped with six machines and presenting ten targets, including singles and doubles. Over the course of four days, 240 targets will be set, with 60 targets to be covered each day, and participants will be organised into six-man squads to compete throughout the event.
Saif Al Zahmi, Director, FMSC, said: “Held under the patronage of H.H. Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah, FMSC draws inspiration from the rich hunting tradition of the region and celebrate its enduring heritage. We are delighted to announce the launch of the website, kicking off the most anticipated return of the event with many new additions in February 2025. Moreover, it is a unique sporting event with over AED 1,000,000 in prizes and a chance to experience the region's vibrant culture. The competition, along with exciting side events, promises an exhilarating experience while respecting the environment through the use of ammunition with 100% natural biodegradable wads and eco-friendly clay targets suitable for all ages.”
One of the highlights of the 2025 edition is side events such as Pool Shoots and English Sporting, which will be held from February 1 to 7. Additionally, the latest edition of the championship is organised with the support of the National Sporting Clays Association and the Clay Pigeon Shooting Association, features George Digweed MBE, a renowned English sport shooter and multiple world and European clay-shooting champion; Phil Gray and Saif Bin Futtais, an Emirati sport shooter and five-time Olympian, as ambassadors.
For more information, visit fmsc.ae.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909161040/en/
Contacts
Tarek Kamal El Dine, +971 50 8829649
Tarek Kamal El Dine, +971 50 8829649
tarek@cpo.fujairah.ae
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom